Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients

Clinical Therapeutics
Russell G PostierTigecycline 200 Study Group

Abstract

Tigecycline is a broad-spectrum glycylcycline antibiotic being investigated for the treatment of serious infections in hospitalized patients. Tigecycline has been shown to be efficacious against serious infections in animals, and preliminary studies in healthy adults have shown that tigecycline has an acceptable tolerability profile. This study compared the clinical and microbiological efficacy, pharmacokinetic properties, and tolerability of 2 doses of tigecycline in hospitalized patients with a complicated skin and skin-structure infection (cSSSI). This Phase II, randomized, open-label study was conducted between September 1999 and March 2001 at 14 investigative centers across the United States. Patients were randomized to receive tigecycline 25 or 50 mg IV q12h for 7 to 14 days. The primary efficacy end point was the clinically observed cure rate among clinically evaluable (CE) patients at the test-of-cure visit. Secondary end points were the clinical cure rate at the end of treatment and bacteriologic response in microbiologically evaluable (ME) patients. Also, in vitro tests of susceptibility to tigecycline were performed for selected pathogens known to cause skin infections, including methicillin-resistant and methicillin...Continue Reading

References

Jan 5, 2002·Current Opinion in Pharmacology·I Chopra

❮ Previous
Next ❯

Citations

Jul 4, 2006·Indian Journal of Pediatrics·Hossam Al-TatariBasim Asmar
Mar 31, 2006·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·F S TacconeF Jacobs
Feb 2, 2006·Current Infectious Disease Reports·Matthew E Levison, Shirley Fung
Mar 2, 2005·International Journal of Antimicrobial Agents·Dilip Nathwani
May 12, 2005·International Journal of Antimicrobial Agents·John E ConteElisabeth Zurlinden
Aug 3, 2007·International Journal of Antimicrobial Agents·A L CaseyT S J Elliott
Feb 16, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Stan Deresinski
Aug 5, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Gary E Stein
Aug 5, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Gary A Noskin
Aug 5, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alison K MeagherEvelyn J Ellis-Grosse
Jul 14, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Gary E Stein, William A Craig
Mar 3, 2006·Surgical Infections·Mark H Wilcox
Mar 14, 2009·The Journal of Antimicrobial Chemotherapy·F Kate GouldUNKNOWN MRSA Working Party of the British Society for Antimicrobial Chemotherapy
Jun 21, 2011·The Journal of Antimicrobial Chemotherapy·Dafna YahavLeonard Leibovici
Jan 2, 2007·The Pediatric Infectious Disease Journal·George A Pankey, Russell W Steele
Nov 18, 2006·International Journal of Clinical Practice·M L TownsendR H Drew
Dec 24, 2004·Antimicrobial Agents and Chemotherapy·Gopal MuralidharanSteven Troy
Oct 28, 2005·Antimicrobial Agents and Chemotherapy·Johannes BreedtUNKNOWN Tigecycline 305 cSSSI Study Group
Mar 29, 2005·Antimicrobial Agents and Chemotherapy·Gopal MuralidharanSteven M Troy
Jan 6, 2006·Drugs·James E Frampton, Monique P Curran
Jul 14, 2010·Journal of Athletic Training·Steven M ZinderDavid B Vasily
Oct 27, 2005·The Journal of Dermatological Treatment·Noah Scheinfeld
Jan 31, 2006·Expert Review of Anti-infective Therapy·George G ZhanelDaryl J Hoban
Oct 14, 2008·Expert Review of Anti-infective Therapy·Jason J Schafer, Debra A Goff
Aug 19, 2005·Expert Review of Anti-infective Therapy·Adolfo C Fernandez-ObregonCarolyn Willis
Mar 11, 2005·Expert Opinion on Investigational Drugs·Michael N Alekshun
Jun 15, 2005·Expert Opinion on Pharmacotherapy·C Andrew DeRykeDavid P Nicolau
Oct 12, 2007·Expert Opinion on Pharmacotherapy·Hisham Ziglam
Jan 26, 2006·Expert Opinion on Investigational Drugs·Ronald A Squires, Russell G Postier
May 1, 2010·Current Medical Research and Opinion·J Floris S LogmanBen A van Hout
Jul 26, 2011·The Lancet Infectious Diseases·Efthimia TasinaMalamatenia Arvanitidou
Sep 18, 2010·Diagnostic Microbiology and Infectious Disease·Antonio T FreireUNKNOWN 311 Study Group
Apr 21, 2009·Medicina clínica·Fernando Salgado OrdóñezUNKNOWN Sociedad Andaluza de Enfermedades Infecciosas (SAEI)
Sep 15, 2009·Diagnostic Microbiology and Infectious Disease·Julie PassarellEvelyn J Ellis-Grosse
Apr 24, 2009·Enfermedades infecciosas y microbiología clínica·Carmen BetriuJuan J Picazo
Jul 26, 2006·Pharmacotherapy·Warren E Rose, Michael J Rybak
Jun 5, 2007·Pharmacotherapy·James J ZimmermanRichard J Fruncillo
Jan 28, 2010·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·P Muñoz, UNKNOWN AST Infectious Diseases Community of Practice
Nov 19, 2013·Journal of Clinical Pharmacology·Noriaki YamashitaJoan Korth-Bradley
Sep 20, 2006·Clinical Therapeutics·Thien-Ly DoanPaul F Riska
Aug 1, 2006·The Journal of Infection·Adam P Fraise
Aug 5, 2008·Journal of Chemotherapy·S ShakilA U Khan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.